The KRAS G12C inhibitors sotorasib and adagrasib have demonstrated efficacy as monotherapy in KRAS G12C-mutant NSCLC, where roughly 15% of patients have this mutation. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.